New C3 AI Ex Machina Customers Experience Success with No-Code AI Anyone Can Use
June 07 2021 - 8:00AM
Business Wire
C3 AI Ex Machina Enjoys Accelerated Customer
Momentum and Introduces Significant New Capabilities in First Full
Quarter of Release
C3 AI (NYSE:AI), the Enterprise AI application software company,
today announced that C3 AI® Ex Machina, its no-code solution that
anyone can use to generate actionable enterprise AI insights, has
seen significant growth in its first full quarter of release. More
than 25 organizations and companies are now generating predictive
insights and reaping the benefits that no-code enterprise AI
provides, including energy giant Con Edison, healthcare leader
Stanford Medicine, and the HIVE Lab at George Washington
University.
Today, organizations are actively working to better understand
how they can apply the power of enterprise AI to deliver predictive
insights and improve business outcomes. As the only complete
no-code AI/ML solution, C3 AI Ex Machina enables analysts,
operators, and subject matter experts to develop, scale, and apply
enterprise AI insights without the computer and data science
background typically required to develop complex code for AI-based
applications. C3 AI Ex Machina’s easy to use, yet extensive
capabilities, provide users with the tools they need to quickly
ingest and prepare petabytes of data, construct precise ML models
with AutoML, and generate actionable insights and applications they
can deploy across their organization. The product also allows
individuals, teams, and organizations to collaborate and scale with
confidence using the C3 AI Suite – a tried, tested, and proven
end-to-end enterprise AI platform – to apply the power of
predictive analytics against digital transformation
initiatives.
Since its January 2021 launch, C3 AI Ex Machina customers are
deriving insights across a diverse set of industries and use cases,
including medical research, sales forecasting, international trade
analytics, patient care, marketing analysis, and more.
C3 AI has continued to expand and enhance the features and
capabilities offered in C3 AI Ex Machina, with innovations in
AutoML and feature transformation. And, with the release of Version
7.20 of the C3 AI Suite in May 2021, C3 AI Ex Machina has further
improved the user experience, with additions such as multiple cross
validation methods, new feature engineering nodes to improve model
results, a canvas mini-map, and a searchable templates page. New
save and load data nodes enable users to automatically save and
version analysis and input/output data, allowing experiments to be
reproducible. In addition, users now have access to a new Splunk
data connector, along with a comprehensive set of existing
connectors for popular data stores such as Snowflake, SAP, AWS S3,
Azure Data Lake, Oracle, Salesforce, and others.
“C3 AI Ex Machina empowers anyone to apply the predictive power
of enterprise AI to their work. As a Bioinformatics Lab, we are
always looking for additional avenues to complement our biomedical
expertise with advanced data science techniques,” said Stephanie
Singleton, Section Lead for Microbiome Research with the HIVE Lab
at the George Washington School of Medicine and Health Sciences.
“Our team was able to easily integrate previously developed models
into the C3 AI Ex Machina environment and improve those models
through its AutoML capabilities, robust model evaluation metrics,
and user-friendly interface. C3 AI Ex Machina has allowed us to
scale our work in predictive intervention and treatment selection
for patients with epilepsy and diabetes, and we're excited to
continue our partnership with C3 AI to drive better patient
outcomes."
“We’ve been incredibly pleased with the uptake and interest C3
AI Ex Machina has generated since its official launch earlier this
year,” said C3 AI President and CTO Ed Abbo. “More and more
organizations have discovered the incredible value enterprise
AI-powered insights can deliver, and C3 AI Ex Machina’s no-code
approach represents the fastest and simplest way for anyone to
start surfacing those insights to generate improved business
outcomes.”
Learn more about C3 AI Ex Machina and try the application
here.
About C3.ai, Inc.
C3.ai, Inc. (NYSE:AI) is the Enterprise AI application software
company that accelerates digital transformation for organizations
globally. C3 AI delivers a family of fully integrated products: C3
AI® Suite, an end-to-end platform for developing, deploying, and
operating large-scale AI applications; C3 AI Applications, a
portfolio of industry-specific SaaS AI applications; C3 AI CRM, a
suite of industry-specific CRM applications designed for AI and
machine learning; and C3 AI Ex Machina, a no-code AI solution to
apply data science to everyday business problems. The core of the
C3 AI offering is an open, model-driven AI architecture that
dramatically simplifies data science and application development.
Learn more at: www.c3.ai.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210607005263/en/
C3 AI Public Relations Edelman Lisa Kennedy 415-914-8336
pr@c3.ai
Investor Relations ir@c3.ai
C3 AI (NYSE:AI)
Historical Stock Chart
From Jun 2024 to Jul 2024
C3 AI (NYSE:AI)
Historical Stock Chart
From Jul 2023 to Jul 2024